ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative4.4 M4.86 M4.56 M4.19 M4.85 M18.46 MRicerca e sviluppo3.42 M3.11 M3.11 M3.27 M8.24 M17.73 MReddito operativo-5.11 M-6.5 M-19.78 M-3.79 M-6.55 M-36.62 MProventi non operativi, Totale1.86 M2.36 M-10.58 M-25.97 M2.16 M-32.03 MOneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari2.55 M2.55 M-10.61 M-25.97 M2.13 M-31.9 MEntrate/uscite straordinarie-689 K-185 K26 K027 K-132 KUtile al lordo delle imposte-3.25 M-4.14 M-30.36 M-29.75 M-4.39 M-68.65 MQuota di utile——————Imposte0000-7.13 M-7.13 MInteressi di minoranza23 K-4 000100 K29 K41 K166 KAltri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate-3.27 M-4.14 M-30.46 M-29.78 M851 K-63.53 MAttività cessate——————Utile netto-3.27 M-4.14 M-30.46 M-29.78 M851 K-63.53 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-3.27 M-4.14 M-30.46 M-29.78 M851 K-63.53 MUtile base per azione (EPS base)0-0.02-0.13-0.13-0-0.28Utile diluito per azione (EPS diluito)0-0.02-0.13-0.13-0-0.28Numero medio di azioni ordinarie in circolazione200.19 M226.05 M228.36 M228.85 M230.12 M913.38 MAzioni diluite in circolazione200.19 M226.05 M228.36 M228.85 M230.12 M913.38 MEBITDA49.87 M-6.49 M-19.77 M-3.77 M-6.53 M-36.56 MEBIT-5.11 M-6.5 M-19.78 M-3.79 M-6.55 M-36.62 MCosto del fatturato154 K36 K————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)54.98 M14 K14 K15 K16 K59 K
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.